GLP-1 for Weight Loss
New Service at OCQ: Non-surgical treatment of obesity
Exploring new therapies for Diabetes & Obesity:
Introduction
GLP-1 (Glucagon-Like Peptide-1) is a hormone regulating blood sugar and appetite.
GLP-1 receptor agonists (analogues) are transforming diabetes and obesity treatment.
Research is expanding into injectable and oral small molecule alternatives.
Why GLP-1 is important
Supports insulin release, reduces glucagon output, slows gastric emptying, aids weight loss and improves metabolic and heart health.
Benefits:
- Effective blood sugar control
- Significant weight reduction
- Improved heart outcomes
Limitations:
- Mostly injectable
- High cost
- GI side effects (nausea, vomiting)
Current GLP-1 Therapies
Injectables such as Semaglutide (Ozempic), Liraglutide (Saxenda), Dulaglutide (Trulicity), Trizepatide (Mounjaro)
The Rise of Small Molecule GLP-1 Agonists & Future Outlook
GLP-1 analogues are transforming diabetes and obesity care. Small molecule GLP-1 agonists promise a major leap forward: oral tablets with strong results in glucose control and weight loss. Early trials show strong results in glucose control and weight loss, with ongoing studies set to confirm safety, efficacy, and long-term benefits. With next-gen combinations, personalised therapies, and a market projected to top $100B by 2030, they’re set to redefine metabolic medicine.
Make an appointment with our friendly staff to explore non-surgical weight loss options.